Praxis Precision Medicines PRAX 深 沪
交易中 03-30 11:57:55 美东时间
283.85
-6.250
-2.15%
华盛通- 最 高296.00
- 今 开291.59
- 成交量 13.93万股
- 最 低 282.50
- 昨 收 290.10
- 总市值 79.05亿
- 52周最高 355.9999
- 市盈率 静 --
- 换手率 0.50%
- 52周最低 26.70
- 委 比 0.00%
- 总股本 2785.08万
- 历史最高 914.265
- 量 比 0.89
- 振 幅 4.65%
- 历史最低 11.85
- 每 手 1
- 风险率 116.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Pyxis Oncology, Inc. reported updates on its lead candidate MICVO, including completion of target enrollment in a Phase 1 monotherapy study for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the first quarter of 2026. The company also announced updated data expected in mid-2026, which will include patients treated with modified weight-based dosing. Additionally, Pyxis Oncology shared financial results for 2025, includin...
03-23 11:00
Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures
Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner, with FDA filing planned for 2026.
03-09 21:26
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines granted restricted stock unit awards covering 2,931 shares to 14 new non-executive employees under its 2024 Inducement Plan. The awards, granted on March 2, 2026, vest in four equal annual installments and are contingent on continued employment. The company, focused on CNS precision neuroscience, develops therapies for genetic epilepsies and neuronal excitation-inhibition imbalances using its proprietary platforms Cereb...
03-04 21:01
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
美股大行评级 | 潜在涨幅214.14%！HC Wainwright & Co.：Ardelyx获机构升目标价至18美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Ardelyx"买入"评级，目标价从10美元升至18美元；Truist Securities：维持Praxis Precision Medicine"买入"评级，目标价从500美元升至700美元
02-23 08:56
Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported a wider-than-expected l...
02-21 01:10
Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $130
Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price target from $95 to $130.
02-20 21:24
U.S. RESEARCH ROUNDUP-Dropbox, Etsy, Zscaler
U.S. RESEARCH ROUNDUP-Dropbox, Etsy, Zscaler Feb 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Dropbox, Etsy and Zscaler , on Friday. HIGHLIGHTS * Akamai Technologies Inc AKAM.O : Scotiabank raises target price to $
02-20 15:08
财报速睇 | Praxis Precision Medicines, Inc. 2025财年Q4营收0.00亿美元，同比下降100.0%；归母净利润亏损0.89亿美元，同比亏损扩大50.8%
华盛资讯2月19日讯，Praxis Precision Medicines, Inc.公布2025财年Q4业绩，公司Q4营收0.00亿美元，同比下降100.0%，归母净利润亏损0.89亿美元，同比亏损扩大50.8%。
02-19 21:20
Praxis Precision posts bigger Q4 loss as R&D costs grow
Praxis Precision posts bigger Q4 loss as R&D costs grow Overview CNS biopharmaceutical firm reported wider Q4 net loss of $88.9 mln, with increased R&D expenses Praxis submitted NDAs for ulixacaltamide and relutrigine to the FDA Company raised $621 mln in January 2026 public offering, funding operat
02-19 20:40
